<DOC>
	<DOCNO>NCT00162799</DOCNO>
	<brief_summary>To explore efficacy triflusal attenuation insulin resistance human obesity . Triflusal salicylate compound approve several country antithrombotic agent ( antiplatelet ) . The hypothesis explore reduction obesity-induced insulin resistance triflusal .</brief_summary>
	<brief_title>Efficacy Pilot Study Triflusal Attenuation Insulin Resistance Human Obesity</brief_title>
	<detailed_description>Double-blind , randomize , cross-over ( three period ) two dose level triflusal , placebo-controlled . Interventions : treatment period Triflusal 600 mg/d , 15 day Triflusal 900 mg/d , 15 day placebo , 15 day Washout period : 30 day</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Triflusal</mesh_term>
	<mesh_term>Salicylates</mesh_term>
	<criteria>Ages 35 60 year old</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>insulin resistance inflamation</keyword>
	<keyword>insulin sensitibity</keyword>
	<keyword>obesity-induced insuline resistence</keyword>
	<keyword>obesity-diabetes link</keyword>
	<keyword>salicylate</keyword>
	<keyword>insulin resistance obesity health adult</keyword>
</DOC>